Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Calidi Biotherapeutics, Inc. Common Stock
(NY:
CLDI
)
0.2164
-0.0206 (-8.69%)
Official Closing Price
Updated: 8:00 PM EDT, May 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Calidi Biotherapeutics, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Study Uncovers Why the Risk of Breast Cancer Increases with Age
May 01, 2026
Via
Investor Brand Network
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
April 30, 2026
Via
Chartmill
On Wednesday, there are stocks with unusual volume. Let's take a look.
↗
April 29, 2026
Via
Chartmill
Curious about the most active stocks on Tuesday?
↗
April 28, 2026
Via
Chartmill
Early Trial Suggests mRNA Vaccine Could Be Effective Against Pancreatic Cancer
April 22, 2026
Via
Investor Brand Network
Scientists Discover Why Immunotherapy Frequently Fails
February 04, 2026
Via
Investor Brand Network
RedChip's Biotech Virtual Investor Conference Replays Now Available
April 21, 2026
Via
ACCESS Newswire
New AI Tool Could Boost the Early Detection of Lung Cancer
April 16, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
New Urine Test Boosts Forecasting of Treatment Outcomes in Bladder Cancer
April 13, 2026
Via
Investor Brand Network
Immunotherapy Could Be Boosted by Blocking the Removal of Cancer RNA
April 10, 2026
Via
Investor Brand Network
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
April 07, 2026
Via
ACCESS Newswire
Report Forecasts the Cancer Immunotherapy Market Hitting $311.4B by 2031
April 02, 2026
Via
Investor Brand Network
Research Suggests the Thymus is Critical in Immunotherapy Outcomes
March 30, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Major Discovery Could Reshape Cancer Immunotherapy
March 27, 2026
Via
Investor Brand Network
Oncolytic Virus Therapy is Set to Transform Cancer Care
March 20, 2026
Via
Investor Brand Network
Scientists Discover Why Colon Cancer Diagnoses are Increasing in Young Adults
March 18, 2026
Via
Investor Brand Network
Microbial Ecosystems Play a Big Role in the Efficacy of Cancer Immunotherapy
March 13, 2026
Via
Investor Brand Network
Unusual volume stocks in Tuesday's session
↗
March 10, 2026
Via
Chartmill
Ongoing Digital Monitoring Could Make Immunotherapy More Accessible
March 09, 2026
Via
Investor Brand Network
OSU Researchers Develop Nanomaterial That Eliminates Cancer Cells
March 06, 2026
Via
Investor Brand Network
UCLA Researchers Develop Method to Fix Fuel Shortages in Cancer Immunotherapy
February 27, 2026
Via
Investor Brand Network
Engineered Nanoparticles Hold Promise in Delivering Precision Cancer Treatments
February 25, 2026
Via
Investor Brand Network
Cancer Stress Protein Enables Tumors to Evade the Immune System
February 20, 2026
Via
Investor Brand Network
Existing Cancer Drug Shows Potential in Reactivating Immunotherapy
February 17, 2026
Via
Investor Brand Network
Early Symptoms of Lung Cancer You Could Be Ignoring
February 12, 2026
Via
Investor Brand Network
Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies
February 05, 2026
Via
Investor Brand Network
Circadian Regulation Could Boost Cancer Immunotherapy, New Study Finds
January 29, 2026
Via
Investor Brand Network
Novel Therapy Helps Tumor Cells Welcome Cancer Treatment
January 28, 2026
Via
Investor Brand Network
Scientists Develop Next-Gen Antibodies That Boost the Body’s Cancer Killing Cells
January 21, 2026
Via
Investor Brand Network
Study Discovers Molecule of Gut Bacteria That Boosts Immunotherapy Response
January 20, 2026
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.